REG - BkofA Merrill Lynch Horizon Therapeutics - 20230921_HORIZON THERAPEUTICS PLC_38.5 (b)_BOFAS

AmgenAnnouncement

22/09/2023 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230922:nRSV3877Na&default-theme=true

RNS Number : 3877N  Bank of America Merrill Lynch  22 September 2023

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader             BofA Securities, Inc.
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             21/09/2023

BofA Securities, Inc.

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

21/09/2023

 

 2.  INTERESTS AND SHORT POSITIONS

 (a)  Interests and short positions (following dealing) in the class of relevant
      security

dealt in (Note 2)

 Class of relevant security: Common             IE00BQPVQZ61
                                                Long             Short
                                                Number   %       Number   %
 (1)  Relevant securities                       521,338  0.228%  83,310   0.036%
 (2)  Derivatives (other than options):         95,622   0.042%  66,844   0.029%
 (3)  Options and agreements to purchase/sell:  0        0%      0        0%
 Total                                          616,960  0.269%  150,154  0.066%

521,338

0.228%

83,310

0.036%

 (2)  Derivatives (other than options):

95,622

0.042%

66,844

0.029%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

616,960

0.269%

150,154

0.066%

 

 (b)  Interests and short positions in relevant securities of the company, other
      than the

class dealt in (Note 2)

 Class of relevant security:
                                                Long         Short
                                                Number  %    Number  %
 (1)  Relevant securities                       0       0%   0       0%
 (2)  Derivatives (other than options):         0       0%   0       0%
 (3)  Options and agreements to purchase/sell:  0       0%   0       0%
 Total                                          0       0%   0       0%

0

0%

0

0%

 (2)  Derivatives (other than options):

0

0%

0

0%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

 3.  DEALINGS (Note 3)

 (a)  Purchases and sales

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Purchase       383                            115.5 USD
 Purchase       300                            115.51 USD
 Purchase       600                            115.52 USD
 Purchase       200                            115.525 USD
 Purchase       1,100                          115.53 USD
 Purchase       7,500                          115.535 USD
 Purchase       316                            115.54 USD
 Purchase       406                            115.6 USD
 Purchase       150                            115.64 USD
 Purchase       30                             115.65 USD
 Purchase       139                            115.63 USD
 Purchase       14                             115.62 USD
 Purchase       8,149                          115.59 USD
 Purchase       139                            115.61 USD
 Purchase       509                            115.58 USD
 Purchase       500                            115.575 USD
 Purchase       1,850                          115.585 USD
 Purchase       70                             115.56 USD
 Purchase       3                              115.55 USD
 Purchase       151                            115.57 USD
 Purchase       2                              115.69 USD
 Purchase       1,400                          115.665 USD
 Purchase       5,500                          115.67 USD
 Purchase       200                            115.675 USD
 Purchase       1806                           115.68 USD
 Purchase       274                            115.66 USD
 Purchase       100                            115.685 USD
 Purchase       1023                           115.7 USD
 Purchase       5                              115.706 USD
 Purchase       2                              115.71 USD

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Sale           2,438                          115.5 USD
 Sale           13                             115.52 USD
 Sale           3                              115.53 USD
 Sale           30                             115.6 USD
 Sale           12                             115.65 USD
 Sale           6                              115.63 USD
 Sale           12                             115.62 USD
 Sale           12                             115.59 USD
 Sale           16                             115.61 USD
 Sale           6                              115.58 USD
 Sale           6                              115.66 USD

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction        Number of relevant securities  Price per unit

e.g. CFD
(Note 5)                    (Note 6)
(Note 4)
 Swaps          Increasing a Short Position  388                            115.501 USD

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 4)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 4)
 N/A                N/A                   N/A

 

 (d)  Other dealings (including transactions in respect of new securities) (Note 3)

 Nature or transaction  Details  Price per unit
 (Note 7)
(if applicable) (Note 4)
 N/A                    N/A      N/A

 

 4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 None

 

 Is a Supplemental Form 38.5(b) attached? (Note 8)  No

 

 Date of disclosure                            22/09/2023
 Contact name                                  Frank Lui
 Telephone number                              +44207 996 6418
 Name of offeree/offeror with which connected  AMGEN INC
 Nature of connection (Note 9)                 Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPFZGZLLZZGFZG